Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer by Hijaz, Miriana et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Neurology Articles Neurology 
3-15-2016 
Folic acid tagged nanoceria as a novel therapeutic agent in 
ovarian cancer. 
Miriana Hijaz 
Henry Ford Health System, MHIJAZ1@hfhs.org 
Soumen Das 
Ismail Mert 
Henry Ford Health System 
Ankur Gupta 
Zaid Al-Wahab 
Henry Ford Health System 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/neurology_articles 
Recommended Citation 
Hijaz M, Das S, Mert I, Gupta A, Al-Wahab Z, Tebbe C, Dar S, Chhina J, Giri S, Munkarah A, Seal S, and 
Rattan R. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer. BMC Cancer 2016; 
16(1):220. 
This Article is brought to you for free and open access by the Neurology at Henry Ford Health System Scholarly 
Commons. It has been accepted for inclusion in Neurology Articles by an authorized administrator of Henry Ford 
Health System Scholarly Commons. 
Authors 
Miriana Hijaz, Soumen Das, Ismail Mert, Ankur Gupta, Zaid Al-Wahab, Calvin Tebbe, Sajad Dar, Jasdeep 
Chhina, Shailendra Giri, Adnan R. Munkarah, Sudipta Seal, and Ramandeep Rattan 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
neurology_articles/292 
RESEARCH ARTICLE Open Access
Folic acid tagged nanoceria as a novel
therapeutic agent in ovarian cancer
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Jasdeep Chhina1, Shailendra Giri4,5, Adnan Munkarah1,5, Sudipta Seal2,6 and Ramandeep Rattan1,5*
Abstract
Background: Nanomedicine is a very promising field and nanomedical drugs have recently been used as therapeutic
agents against cancer. In a previous study, we showed that Nanoceria (NCe), nanoparticles of cerium oxide, significantly
inhibited production of reactive oxygen species, cell migration and invasion of ovarian cancer cells in vitro, without
affecting cell proliferation and significantly reduced tumor growth in an ovarian cancer xenograft nude model.
Increased expression of folate receptor-α, an isoform of membrane-bound folate receptors, has been described in
ovarian cancer. To enable NCe to specifically target ovarian cancer cells, we conjugated nanoceria to folic acid
(NCe-FA). Our aim was to investigate the pre-clinical efficacy of NCe-FA alone and in combination with Cisplatin.
Methods: Ovarian cancer cell lines were treated with NCe or NCe-FA. Cell viability was assessed by MTT and
colony forming units. In vivo studies were carried in A2780 generated mouse xenografts treated with 0.1 mg/Kg
NCe, 0.1 mg/Kg; NCe-FA and cisplatinum, 4 mg/Kg by intra-peritoneal injections. Tumor weights and burden scores
were determined. Immunohistochemistry and toxicity assays were used to evaluate treatment effects.
Results: We show that folic acid conjugation of NCe increased the cellular NCe internalization and inhibited cell
proliferation. Mice treated with NCe-FA had a lower tumor burden compared to NCe, without any vital organ
toxicity. Combination of NCe-FA with cisplatinum decreased the tumor burden more significantly. Moreover, NCe-FA
was also effective in reducing proliferation and angiogenesis in the xenograft mouse model.
Conclusion: Thus, specific targeting of ovarian cancer cells by NCe-FA holds great potential as an effective therapeutic
alone or in combination with standard chemotherapy.
Keywords: Folic acid conjugated nanoceria, Ovarian cancer, Nano cerium oxide, A2780, Targeted therapy
Background
Epithelial ovarian cancer is the fifth most common cause
of cancer-related death in women and the most lethal
gynecologic malignancy due to late stage diagnosis and
upfront or eventual resistance to chemotherapy. Epithe-
lial ovarian cancer is responsible for approximately
21,290 new cases and 14,180 deaths in 2015 in the
United States [1]. Despite new treatment modalities and
improvements in diagnostic methods and surgical tech-
niques, only a marginal improvement in survival has
been achieved in the last 15 years and most patients will
eventually have recurrence and succumb to their disease
[2]. Currently, optimal surgical debulking followed by
platinum-based chemotherapy is the backbone of the
ovarian cancer treatment; however, novel treatment mo-
dalities with less toxicity are urgently needed.
Nanotechnology is defined as the science involved in
the design, synthesis, characterization, and manufacturing
of materials at the nanoscale level [3]. There has been a
rapid growth in the nanotechnology field towards the de-
velopment of nanomedicine products to improve thera-
peutic strategies against cancer [4]. These nanomedical
agents have been shown to improve the pharmacokinetic
and pharmacodynamic properties of conventional treat-
ment agents and may enhance the efficacy of existing anti-
cancer compounds with less toxicity [4]. Cerium is a rare
earth metal and when combined with oxygen, can adopt a
fluorite crystalline lattice structure. Nanoceria (NCe)
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particles can reversibly bind oxygen and shift oxidation
states (Ce3+/Ce4+) depending on the environment [5]. This
interconversion of oxidation states gives rise to a large
number of oxygen vacancies on the surface of NCe and is
the key property that makes it a potent antioxidant agent.
Due to its strong antioxidant properties, we have tested
NCe as a therapeutic agent both in vitro and in vivo in
ovarian cancer cells and showed that NCe inhibited the
reactive oxygen species (ROS), vascular endothelial growth
factor induced proliferation and capillary tube formation of
endothelial cells. [6]. NCe also attenuated cell migration
and invasion without affecting the cell proliferation in
ovarian cancer cell lines [6]. Additionally, in vivo treat-
ment of NCe was associated with significant reduction in
tumor growth and accompanied by decreased prolifera-
tion and attenuation of angiogenesis in a nude mouse
model of ovarian cancer. [6]. NCe has also shown antican-
cer activity in other types of cancers including cutaneous
squamous [7], colon [8] and pancreatic cancer [9] models.
Recently, it has been demonstrated that NCe in cancer
cells associated with acidic conditions prefers to act as a
ROS activator, resulting in accumulation of H2O2 [9]. At
acidic pH, NCe becomes an efficient superoxide dismut-
ase mimetic compared to normal pH and converts super-
oxide radicals to H2O2. On the other hand, at acidic pH,
NCe cannot scavenge H2O2 and eventually results in ac-
cumulation of H2O2 in cancer cells. This switch from act-
ing as a superoxide dismutase or catalase mimetic to
H2O2 accumulation has been attributed to the acidity
dependent surface valence states of NCe (Ce3+ or Ce4+)
[7]. This increased generation of ROS may also be one of
the mechanisms of NCe’s antitumor effect.
Folate is a basic component of cell metabolism, DNA
synthesis and repair and essential for both normal and
tumor cells [10]. Two cellular folate uptake pathways
have been identified: transmembrane reduced folate car-
rier and membrane-found folate receptors (FR) [11].
Interestingly, normal cells utilize reduced folate carrier
as a predominant way for folate uptake; however, FR is
poorly expressed or absent in normal cells and strongly
expressed in cancer cells [11]. FRs capture folate from
outside of the cell and the engulfed endosome is trans-
ported to the intracellular compartment [10]. Three iso-
forms of FRs have been identified so far and these
receptors have been the focus of cancer therapy. In-
creased expression of FR-α has been described in various
tumor tissues, including ovarian, endometrial and breast
cancer [12], and higher FR-α expression was found to be
associated with poor chemotherapy response and sur-
vival outcome in ovarian cancer [13]. Monoclonal anti-
bodies against FR-α, namely farletuzumab, combined
with carboplatinum and taxanes was shown to increase
the response rate in platinum-sensitive ovarian cancer
patients [14], but in another study in platinum-resistant/
refractory patients, combination of farletuzumab with
weekly paclitaxel did not reach its endpoint [15]. Not
only were monoclonal antibodies against FR- α investi-
gated for treatment, but cellular entry process of folate
was also utilized for targeted drug delivery in ovarian
cancer by means of linking folate with chemotherapeutic
agents. A combined treatment of vintafolide (EC145), a
conjugate of folate with desacetylvinblastine monohydra-
zide, with liposomal doxorubicin was demonstrated to
improve progression free survival over standard therapy
in a randomized trial of patients with platinum-resistant
ovarian cancer [11].
In the current study, we investigated the preclinical effi-
cacy of targeted delivery of NCe by its conjugation to folic
acid (NCe-FA) alone and in combination with cisplatinum
in inhibiting ovarian cancer growth in vitro and in vivo.
Methods
Cell culture
A2780 and C200 were kindly provided by Dr. Thomas
Hamilton, Fox Chase Cancer Center, Philadelphia, PA.
The cell lines were maintained in Roswell Park
Memorial Institute media (HyClone-ThermoScientific,
Waltham, MA) supplemented with 10 % fetal bovine
serum (BioAbChem) and insulin. Ovarian cancer cell
lines, OVCAR3 and SKOV3 were from ATCC (Manassas,
VA) and grown according to accompanied instructions.
Synthesis and characterization of nanoceria-folic acid
(NCe-FA)
Cerium oxide nanoparticles were synthesized by using
precipitation method. Briefly, Ce(NO)3, 6H2O (99.999 %
pure) were dissolved in deionized water and hydrolyzed
using NH4OH and pH 9 was maintained [16]. The solu-
tion was then stirred for 4 h and the obtained precipitate
was then washed with deionized water 3 times. Finally,
cerium oxide nanoparticles (NCe) were dried over-
night under vacuum at 60 °C. Next, a thin coating of
APTMS on the surface of the cerium oxide nanopar-
ticles was then incorporated. This coating provided
the amine (−NH2) functional group to conjugate folic
acid on the surface of the NCe [17]. Folic acid was
conjugated to the amine functionalized NCe by using
1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydro-
chloride (EDC) and N-hydroxysulfosuccinimide coupling
chemistry [17]. Molar ratio of folic acid:NCe-NH2: N-
hydroxysulfosuccinimide-EDC was 1:1:2.2:11.2. Reac-
tion was carried for 24 h and then washed in both
dimethyl sulfoxide and water to remove the EDC, N-
hydroxysulfosuccinimide and unbound folic acid.
Finally, folic acid conjugated NCe (NCe-FA) were dried
under vacuum at 40 °C. NCe-FA was then characterized by
using high resolution transmission electron microscopy, X-
ray diffraction, X-ray photoelectron spectroscopy and
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dynamic light scattering. Numbers of the folic acid mole-
cules on top of the 1 nanocrystal were then calculated with
help of wet loss from thermogravimetric analysis.
Nanoparticle uptake studies
NCe, NCe-APTMS and NCe-FA were incubated at dif-
ferent concentrations for 24 h. After incubation cells
were washed 3 times using PBS (pH 5) to remove any
surface bound nanoparticles. Cells were then collected
by scraping and inductively coupled plasma mass spec-
troscopy was carried out to quantify uptake of NCe as
describe in a previous publication [18]. To visualize the
uptake of NCe-FA, one million A2780 cells were incu-
bated with NCe-FA, washed and fixed in Trump’s fixa-
tive (1 % glutaraldehyde and 4 % formaldehyde in 0.1 M
phosphate buffer, pH 7.2) for 24 h. Cell pellet was em-
bedded in Spurr’s resin and thin (90 nm) sections were
cut on a Reichert Ultracut E ultramicrotome and placed
on 200 mesh copper grids. Pictures were taken using
Philips Transmission Electron Microscope (TEM) 208 at
the Henry Ford Hospital Electron Microscopy Core.
ROS estimation
ROS was determined using the membrane-permeable
fluorescent dye 6-carboxy2',7'-dicholorohydrofluorescein
diacetate (DCFDA) in serum-free medium as described
previously [6]. A2780 cells 48 h pretreated with NCe or
NCe-FA were treated with 5 μM DCFDA dye and fluor-
escence was measured at excitation 485 nm and emis-
sion 530 nm for various time period from 10 to 60 min
using Synergy H1 hybrid reader monochromator system
(BioTek, Winooski, VT) [6].
Proliferation assay
To determine the effect of nanoparticles on prolifera-
tion of ovarian cancer cells, 4000 cells per well were
plated in 96-well plates in Roswell Park Memorial In-
stitute media containing 10 % (v/v) fetal bovine serum
overnight. The next day, the cells were treated with
indicated concentrations of NCe or NCe-FA (10–100 μM).
Before treatment the NCe and NCe-FA suspension
solution was left undisturbed for 30 min of sedimen-
tation, to get rid of the aggregated particles. Solution
from the top layer was used for all treatments. Cellu-
lar respiration as an indicator of cell number was de-
termined by MTT assay performed at 24, 48 and 72 h
post-treatment as described earlier [19]. MTT was
purchased from Sigma.
ApoTox-Glo Triplex assay
To determine the effect of NCe-FA on survival, cytotox-
icity and apoptosis of ovarian cancer cells, 4000 cells per
well were plated in 96-well plates and treated with indi-
cated concentration of NCe-FA for 48 h. At end of 48 h,
ApoTox-Glo Triplex assay kit (Promega; Madison, WI)
was used as per the manufacturer’s instructions to assess
cell viability and caspase3/7 activity [20]. Briefly, the
assay measures all three parameters in the same cells by
combining fluorescence based measurement of two dif-
ferential proteases biomarkers detecting live cells and
dead cells. A second reagent containing luminogenic
DEVD-peptide substrate for caspase-3/7 and Ultra-Glo™
Recombinant Thermostable Luciferase was added, and
the activity measured with a luminometer. BioTek Syn-
ergy H1 Hybrid Reader (ThermoScientific) was used to
measure the output reads.
Colony formation assay
A total of 2000 cells were plated in triplicates in 6-well
plates and treated with indicated concentrations of NCe
or NCe-FA. The cells were allowed to form colonies for
up to 2 to 4 weeks. Colonies were stained with MTT
and counted as described previously [6].
Animal studies
Ethics statement
All mice were housed and maintained under specific
conditions in facilities at Henry Ford Hospital, Detroit,
MI. The facilities are approved and inspected by the
American Association for Accreditation of Laboratory
Animal Care and managed in full accordance with
current regulations and standards of the U.S. Department
of Agriculture, U.S. Department of Health and Human
Services, and the National Institutes of Health. All studies
were approved and supervised by the Institutional Animal
Care and Use Committee, under the protocol number
1156. Institutional guidelines for the proper and hu-
mane use of animals in research were followed. Mice
were regularly monitored for any distress once tumor
was established and were humanly sacrificed on
reaching the end point. Regular health and well-being
checks were also performed by Henry Ford Hospital
veterinarian staff.
Six-week-old female nude mice were purchased from
the National Cancer Institute-Frederick Cancer Research
and Development Center (Frederick, MD). A2780 cells
at a concentration of 2 × 106/200 μl suspended in PBS
were injected into the intraperitoneal cavity (day 0) of 6
to 7-week-old nude mice as described before [21]. Mice
were randomized into various groups (n = 10). For the
first experiment, Group 1 was treated as the control and
received PBS intraperitoneally, every third day. Group 2:
received NCe treatment at the dose of 0.1 mg/kg body
weight, every third day from 3 days postinoculation of
tumor cells till the end of the study. Group 3 received
NCe-FA treatment at the dose of 0.1 mg/kg body weight,
every third day from 3 days postinoculation of tumor
cells till the end of the study. For the second experiment
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(n = 8 per group), Group 1 acted as the control and PBS
was injected intraperitoneally, every third day. Group 2
received NCe-FA treatment at the dose of 0.1 mg/kg
body weight, every third day from 3 days postinoculation
of tumor cells till the end of the study. Group 3 received
NCe-FA treatment along with cisplatinum treatment at
4 mg/kg of body weight once a week intraperitoneally.
Group 4 received 3 cisplatinum treatments alone at the
dose of 4 mg/kg of body weight once a week. After
tumor induction, mice were monitored daily for signs of
any distress. Regular health checks are also performed
by the veterinarian staff. Mice were humanly sacrificed
when the tumor burden reached the mandate weight in
untreated mice at 4 weeks. Tumors were fixed in forma-
lin for sectioning. Blood was collected in heparin-coated
tubes to obtain plasma. Liver, kidney, heart and spleen
from all animals were formalin fixed and processed. One
tumor and organ slide from each mouse was stained
with hematoxylin and eosin.
Toxicity assays
Blood was collected in heparin-coated tubes immediately
after mouse euthanasia. Plasma was isolated from the
blood and subjected to analysis of a panel of liver func-
tion tests (aspartate aminotransferase, alanine aminotrans-
ferase and albumin) and kidney function tests (creatinine,
urea and albumin) as described before [22]. All assays
were performed using kits from Bioassay Systems follow-
ing the manufacturer’s instruction (Hayward, CA).
Tumor score
Tumor nodules morphology and count were identified
grossly in various organs. These included the liver, kid-
neys, bowel and peritoneum and described before [21].
A score of 0 was given for no nodule in the organ; 1 for
1 nodule; 2 for 2 to 5 nodules and score 3 for more than
5 nodules observed per organ. Two individuals per-
formed the scoring in a blinded manner and included a
gynecology oncology fellow (ZW).
Immunohistochemistry
The tumors excised from mice were fixed in 10 % para-
formaldehyde for 48 h and paraffin-embedded. Consecu-
tive sections of 4 microns thick were cut and processed
for hematoxylin and eosin staining and immunohisto-
chemistry for Ki-67 (used at 1:100; catalog No: M7240,
Dako) and cleaved caspase-3 (used at 1:200, catalog No:
9661, Cell Signaling Technology). Anti-4 Hydroxynone-
nal (4-HNE) antibody (catalog No: ab46545, used at
1:100) and CD31 antibodies were from Abcam (used at
1: 200, catalog No. 28364). Vimentin (used at 1:100,
catalog No: M0725) antibody was obtained from Dako
and staining was performed according to the manufac-
turer’s instruction. The positive cells stained brown. The
slides were examined under a light microscope, and rep-
resentative pictures were taken from a minimum of 4–5
slides from each group [23]. The quantification of the
stain intensity was performed by assigning a score of 0–
1 for no or weak stain; 2 for moderate stain and 3 for
strong stain. All slides were examined in a blinded
manner.
Statistical analysis
Data were statistically analyzed using the Graph Pad
Prism software (GraphPad Software Inc, La Jolla, CA)
using a combination of t-test and analysis of variance
methods.
Results
Synthesis and characterization of Cerium - Folic acid
(NCe-FA)
Folic acid-coated nanoparticles were thoroughly charac-
terized. High-resolution transmission electron micros-
copy images show the size of the NCe-FA is
approximately 10 nm (Fig. 1a). NCe-FA suspension was
also analyzed using dynamic light scattering to identify
the nanoparticles size or extent of agglomeration in
complete cell culture medium (Eagle’s minimum essen-
tial medium with 10 % fetal bovine serum). Figure 1b
shows the histogram for the NCe-FA size distribution.
Cell culture medium was used for dynamic light scatter-
ing measurement as ion and protein rich medium is
known to influence nanoparticles aggregation and all cell
culture experiments were carried out in a similar envir-
onment [24]. The hydrodynamic size of NCe-FA nano-
particles was found as approximately 30 nm with a small
percentage (26 %) having agglomerated particles of size
150 nm. A slight increase in size (~30 nm) may indicate
formation of loose agglomeration and absorption of pro-
tein/ions increase the hydrodynamic size. The surface
charge of the NCe-FA was also analyzed and found to be
25 mV. X-ray diffraction data confirmed the microcrys-
talline nature of the particles (Fig. 1c). X-ray photoelec-
tron spectroscopy spectra of nitrogen 1S revealed folic
acid presence on the surface of the nanoparticles
(Fig. 1d). Characteristic peaks of NCe-FA N1s spectra
was deconvoluted and following peaks were assigned
397.25 eV for C-N = C, 398.6 eV for N-H and 400.8 eV
for N-C =O, which confirmed the presence of folic acid
on the surface of the nanoparticles (Additional file 1:
Fig. S1A). Absence of nitrogen signal for APTMS-NCe
might be due to the presence of a very thin coating
and high signal versus noise ration of the instrument.
X-ray photoelectron spectroscopy spectra of Ce 3d of
NCe, 3-aminopropyl-trimethoxysilane (APTMS)-NCe
and NCe-FA revealed no significant changes in the surface
oxidation state during the reaction/surface modification of
ceria with folic acid (Fig. 1e). X-ray photoelectron
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spectroscopy spectrum was further deconvoluted to deter-
mine the surface oxidation state on the surface of NCe-
FA, as discussed elsewhere (Additional file 1: Fig.
S1B) [22]. Surface oxidation states of NCe-FA play an
important role in determining NCe’s redox activity.
As mentioned earlier, redox activity of NCe is due to
the presence of Ce3+ and Ce4+ on the surface of the
nanoparticles [25]. The Ce3+/Ce4+ oxidation ratio for
NCe-FA was 47.4 %. Weight loss results from ther-
mogravimatric analysis (Fig. 1f ) were used to calculate
approximate numbers of folic acid ligands on the sur-
face of each nanoparticles (assuming NCe diameter is
10 nm according to the transmission electron micros-
copy observation) where NCe-APTMS weight loss
data were used as a baseline (detailed calculations are
shown in the Additional file 2). Weight loss data for
bare NCe, APTMS-NCe and NCe-FA are shown in
Additional file 1: Fig. S1C. Approximate 74 folic acid
molecules were conjugated on the surface of each
NCe-FA particle.
a b
c d
e f
Fig. 1 Detailed characterization of synthesized NCe-FA. a High resolution transmission electron microscopy image of the NCe-FA showed particles
sized 8–10 nm. b The hydrodynamic size of the nanoparticles showed slight agglomeration of the particles in cell culture medium, 76 % of particles in
the range between 20 and 70 nm. c X-Ray T spectrum shows the crystalline property of the nanoparticles. d X-ray photoelectron spectroscopy spectra
of nitrogen 1S of NCe, NCe-EPH and NCe-EPH-FA confirms the presence of folic acid on the surface of the nanoparticles. e X-ray photoelectron
spectroscopy spectra of Ce3d of NCe, NCe-APTMS and NCe-APTMS-FA showed no significant change in surface chemistry (Ce3+/Ce4+) due to
modification of the surface. f Thermogravimetric analysis weight loss spectra for NCe-APTMS and NCe-APTMS-FA showed presence of folic
acid on the surface of the NCe nanoparticle
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NCe-FA showed a higher internalization rate compared to
NCe
Uptake of NCe-FA by the ovarian cancer cells was
assessed by measuring the amount of NCe-FA inside the
cells by mass spectroscopy. Cells were treated with NCe
alone, functionalized NCe with amine (CO2-NH2) by
using APTMS (referred to as NCe) [26] and functional-
ized NCe-FA at a dose range of 0–300 μM. After 24 h,
cells were extensively washed to remove excess or any
surface-attached nanoparticles. Cell pellet was subjected
to mass spectroscopy to determine the amount of nano-
particles inside the cells in terms of parts per billion. A
dose-dependent intake inside the cells was observed with
the conjugation of folic acid with the NCe particles
(Fig. 2a). Further we used TEM to visualize the internal-
ized NCe-FA. In treated A2780 cells NCe-FA particle ag-
glomerates could be observed in distinct vacuoles (2c,
second panel), while no such vacuoles could be detected
in untreated cells (2c, second first panel). Magnified im-
ages of vacuoles are shown in panels three and four
(Fig. 2c). Thus, folic acid conjugation significantly in-
creases the uptake of the cerium nanoparticle by the
cancer cell.
NCe-FA inhibits ROS in A2780 cell line
Recent data point toward an important role for oxida-
tive stress in the etiology of ovarian cancer as ROS
accumulation plays a significant role in the initiation
and progression of ovarian cancer [27, 28]. NCe has
been shown to act as a free radical scavenger by inhi-
biting ROS in ovarian cancer by us and others [29–
31]. Acidic extracellular pH is a major feature of ma-
lignant tissue, which might be secondary to lactate se-
cretion from anaerobic glycolysis [32, 33]. It was
demonstrated that the NCe nanoparticle aids in gen-
eration of ROS in cancer cells [9]. We observed that
an acidic NCe significantly increased ROS with time
(Fig. 2b) in A2780 measured by using DCFDA dye
followed by fluorescence reading kinetics up to 6 h.
To investigate if tagging of folic acid had any effect
on its ROS generating property, we examined the ef-
fect of NCe-FA on ROS generation. Interestingly,
NCe-FA treatment also increased ROS generation
compared to control cells, but at significantly lower
levels, compared to NCe particles (Fig. 2b). This indi-
cates that conjugation of folic acid may be comprom-
ising the redox modulating capabilities of NCe.
NCe-FA inhibits ovarian cancer growth in vitro
Our previous data with NCe had shown no effect on
proliferation of ovarian cancer cells [6]. Therefore, we
aimed to determine if NCe-FA conjugation has an effect
on the growth of ovarian cancer cells in vitro due to its
increased cellular uptake. To investigate this, A2780
were treated with various concentrations of NCe-FA
(10–100 μM) and cellular respiration as an indicator of
viable cell number was determined by 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay [19]. NCe treatment had no significant effect on
the proliferation of A2780, consistent with our previ-
ous results (Fig. 2d). However, NCe-FA showed sig-
nificant inhibition in viable cells in A2780 cells
(Fig. 2d, black bars). More effective inhibition was ob-
served in the colony formation assay, where NCe-FA
significantly inhibited the colony forming units in
A2780 (Fig. 2e, black bars). Similar inhibition of via-
bility and colonogenic survival by NCe-FA in other
ovarian cancer lines: SKOV3, OVCAR 3 and C200
was also seen (Additional file 3: Fig. S2). To further
validate the reduction in cell number by NCe-FA, we
assessed the cell viability, cytotoxicity and caspase7/3
activity simultaneously [20], in A2780 after 48 h of
NCe-FA treatment. NCe-FA treated cells showed sig-
nificant decreased cell viability, increased cell death
and caspase 7/3 activation (Fig. 1f-h). These data sug-
gest that by tagging folic acid we enabled NCe to de-
crease cell variability, possibly due to its increased
internalization resulting in apoptosis.
NCe-FA inhibits ovarian cancer in vivo
Preclinical evaluation of NCe-FA treatments was done
in A2780 xenografts bearing nude mice that were
treated with either vehicle PBS or NCe (0.1 mg/kg
body weight) or NCe-FA (0.1 mg/kg body weight).
Mice treated with NCe-FA reflected slower tumor
growth as seen by lower mice weights compared to
NCe alone and vehicle treated mice (Fig. 3a). Meas-
urement of excised tumor weight showed that NCe-
FA was more effective in inhibiting tumor growth
(Fig. 3b), indicating that conjugation of folic acid po-
tentiated the efficacy of NCe alone.
The injected cancer cells also homed to the ovary and
formed ovary associated tumors, along with spread to
the other organs. Ovary associated tumors were excised
individually, examined and measured. The pictograph in
Additional file 4: Fig. S3 shows that NCe-FA associated
ovary tumors were less in size. Also, involvement of only
1 ovary was associated more with NCe-FA treated mice,
with some mice showing no ovary involvement at all.
This indicated that NCe-FA is effective in reducing the
ovary-associated tumor spread.
NCe-FA treated mice had lower tumor burden compared
to NCe and vehicle groups
Tumor burden at vital organ sites was enumerated by
assigning a score of 0 if no tumor nodules were ob-
served; 1 for 1 nodule; 2 for 2 to 5 nodules and a
score of 3 for more than 5 nodules [21]. All organs
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examined (peritoneum, bowel, liver and kidney) from
the NCe-FA treated group showed a significantly
lower score compared to vehicle and NCe treated
mice (Fig. 3c–f ). The greatest difference was observed
in the kidney and liver scores (Fig. 3e, f ), indicating
that NCe-FA has the potential to contain metastatic
spread of ovarian cancer, which could be in part due
to restriction of tumor size.
NCe-FA treated mice did not show any signs of vital
organ toxicity
We determined the cellular toxicity of NCe-FA on liver,
heart, spleen, kidney and lungs. Formalin fixed organs
from untreated and NCe-FA treated mice at the end of
the study were stained for hematoxylin and eosin. Exam-
ination of the sections revealed that the morphology of
all organs from treated and untreated mice appeared to
Fig. 2 NCe-FA internalizes and inhibits ovarian cancer cell proliferation. a Increasing concentrations of the various nanoparticles measured inside
the cancer in a dose-dependent manner. b ROS generated by NCe and NCe-FA over a period of time. c Representative TEM pictures of cells with
vacuoles containing NCe-FA particle. Panels 1 and 2 show images from control and NCe-FA treated cells at a magnification of 18000. Panels 3
and 4 show magnified images of the vacuoles containing NCe-FA particles (magnification 28000). d Decreasing number of cells under NCe-FA
treatment compared to NCe alone at 48 h as seen by MTT assay. e Decreasing number of colonies formed under NCe-FA treatment compared
to NCe alone as observed by clonogenic survival assay. f Decreased protease-based cell viability under NCe-FA treatments at 48 h. Values are
represented as percent of control, with control taken as 100 % viable cells. g Increased protease-based cell cytotoxicity under NCe-FA treatments
at 48 h. Values are represented as percent of control. h Caspase 7/3 activity under NCe-FA treatments at 48 h, with values represented as percent of
control. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 compared to control cells
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be normal and there were no findings suggestive of tis-
sue necrosis (data not shown). No significant difference
in the plasma levels of liver function (aspartate amino-
transferase, alanine aminotransferase, and albumin) and
kidney function tests (creatinine, urea, albumin and uric
acid) collected from untreated and treated mice was ob-
served, and they were all within normal limits in both
groups (Additional file 5: Fig. S4). Taken together, these
data showed that NCe-FA treatment twice a week for
4 weeks at the dose of 0.1 mg/kg is safe and not associ-
ated with any abnormal physiological abnormalities or
cytotoxicity.
NCe-FA enhances cisplatinum's tumoricidal effect
We investigated if combination of NCe-FA with cisplati-
num will be more effective in inhibiting ovarian cancer
growth. A2780 xenografts were treated with NCe-FA
(0.1 mg/kg body weight) as before, with or without cis-
platinum (4 mg/kg body weight). Vehicle and cisplati-
num alone treatments served as comparative controls.
While NCe-FA treated mice had lower weights at the
end of 4 weeks, cisplatinum treatments caused a signifi-
cant decrease in tumor weight, as expected (Fig. 4a). Ex-
cised tumor mass was the lowest in the combination
group (Fig. 4b), even though the cisplatinum alone
Fig. 3 NCe-FA inhibits A2780 ovarian tumor growth in vivo. a Each mouse weight at the time of sacrifice at 4 weeks post-tumor inoculation.
b Weight of the tumor mass excised from each mouse of the respective group. Clinical score enumerated as the number of tumor nodules
observed by naked eye at each organ site of the c peritoneum, d bowel, e liver and f kidney. A score of 0 was given for no nodules in the
organ; 1 for 1 nodule; 2 for 2 to 5 nodules and score 3 for more than 5 nodules observed per organ
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group had lower body weights. Enumeration of tumor
burden and spread by clinical score in all vital organs [21],
showed NCe-FA/cisplatinum combination to have re-
duced tumor burden at peritoneum and liver (Fig. 4c, e).
Tumor scores at bowel and kidney were significantly less
in the combination treatment group compared to the
NCe-FA group alone, but they did not achieve significance
compared to the cisplatinum group alone (Fig. 4d, f ). This
demonstrates that the decreased tumor score observed in
the NCe-FA treatment group was further lowered by cis-
platinum combination (Fig. 4c–f ). Thus, combination of
NCe-FA with cisplatinum is an effective strategy to inhibit
ovarian tumor growth in vivo.
NCe-FA and combination with cisplatinum reduced the
proliferation and angiogenesis
In order to ascertain the proliferation of cancer cells,
immunohistochemical analysis of Ki67 was performed.
Fig. 4 NCe-FA enhances cisplatin toxicity in A2780 ovarian tumors in vivo. a Each mouse weight at the time of sacrifice at 4 weeks post-tumor
inoculation. b Weight of the tumor mass excised from each mouse of the respective group. Clinical score enumerated as the number of tumor
nodules observed by naked eye at each organ site of the c peritoneum, d bowel, e liver and f kidney. A score of 0 was given for no nodules
in the organ; 1 for 1 nodule; 2 for 2 to 5 nodules and score 3 for more than 5 nodules observed per organ
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Enumeration of Ki-67 positive cells counted over 5 high
power fields of 5 sections from each group showed sig-
nificantly less Ki-67 positive cells in NCe-FA treated xe-
nografts compared to the untreated group (expressed in
percentages; Fig. 5a), indicating that less number of cells
were proliferating under NCe-FA treatment. The prolif-
eration was further decreased when NCe-FA was com-
bined with cisplatinum. Based on these results, we
suggest that NCe-FA has the ability to restrict ovarian
tumor growth in vivo due to decreased proliferation of
ovarian cancer cells. Since NCe was shown previously by
us to inhibit angiogenesis by targeting endothelial specif-
ically, we also performed CD31 staining to analyze
angiogenesis in the conjugated groups. CD31 staining of
NCe-FA and NCe-FA and cisplatinum treated A2780 tu-
mors demonstrated lower numbers of CD31 positive
microvessels (Fig. 5b) compared to the untreated group.
However, there was no difference between the NCe-FA
and cisplatinum only groups. Since we have previously
observed NCe to inhibit migration and invasion of ovar-
ian cancer cells, we stained for markers of epithelial-
mesenchymal transition (EMT) to observe if NCe-FA
has any effect on the EMT process in vivo. Vimentin, a
marker for mesenchymal phenotype of the cells and one
of the most common markers of EMT [34], was
expressed highly on the membrane of the untreated tumors.
NCe-FA treated tumors showed significantly reduced num-
ber of positively stained cells and the intensity of the stain
alone and in combination with cisplatin (Fig. 5c). Cisplatin
by itself did not affect vimentin expression. We also stained
for epithelial-Cadherin, but could not detect any expression
in the treated or untreated tumor section (data not shown).
These findings suggest that NCe-FA/cisplatinum is effect-
ive in reducing angiogenesis and EMT markers in A2780
ovarian cancer xenograft model.
Combination of cisplatinum with NCe-FA increased cispla-
tinum's apoptotic properties
Cisplatinum is a chemotherapy agent that forms a plat-
inum complex, and once it enters the cell, binds to
DNA, which causes DNA crosslinks as well as oxidative
stress and causes cells to undergo apoptosis [35, 36].
Cleaved caspase-3 is an apoptotic marker and plays a
key role in apoptotic cell death [37]. The combination of
Fig. 5 NCe-FA inhibits proliferation and angiogenesis of ovarian tumors in vivo. a Representative Ki-67 staining of the tumor tissue, indicating
proliferating cells, from various treatment groups (200×). The counts of positive Ki-67 cells from 5 high powered fields (×400) in 3 different xenografts
from each group is presented as a bar graph. ***p < 0.001, #p < 0.05. b Representative CD31 staining of the tumor tissue representing vessel formation
from the various treatment groups (200×). Number of positive staining vessels were counted per field from 5 high powered fields (×400) in 3 different
xenografts from each group and is presented as a bar graph. c Representative vimentin staining of the tumor tissue from the various treatment groups
(400×). Cells with positive membrane stain were counted per field from 5 high powered fields (×400). ***p < 0.001; ns, non-significant
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NCe-FA and cisplatinum had the highest caspase-3
among all of the groups (Fig. 6a). Cisplatinum alone
showed higher activation of caspase-3 compared to
NCe-FA alone. Thus, combination of NCe-FA and cis-
platinum significantly increased apoptosis in ovarian
cancer cells.
Modulation of oxidation status in vivo
Since NCe particles function through the modulation of
their oxidation states, we also observed ROS produc-
tion in vitro by NCe-FA (Fig. 2b). Oxidation status in
the tumor tissue was estimated by 4-HNE immuno-
staining, a commonly used marker for lipid peroxida-
tion and oxidative stress [38]. NCe-FA treated tumors
stained positive for oxidative stress compared to the
control group (Fig. 6b). Cisplatinum treated tumors
showed higher expression of 4-HNE compared to the con-
trol, in agreement with the ROS producing reports of cis-
platinum [39–41]. Tumors treated with the combination
of cisplatinum and NCe-FA exhibited the highest degree
of oxidative stress (Fig. 6b). This suggests that NCe-FA ex-
hibits oxidant property in vivo, probably due to the differ-
ent tumor environment present, and could be one of the
mechanisms behind its elevated antitumor activity in
combination with cisplatinum.
Discussion
In recent years, there has been a tremendous amount of
data accumulation and understanding of tumor biology
that could cause a paradigm shift in the treatment of
cancer. Conventional chemotherapy still constitutes one
of the main strategies for cancer treatment; however, it
lacks the specificity against cancer cells and is associated
with significant toxicity. Nanotechnology has recently
been added to the treatment armamentarium with the
aim to expand the horizons of cancer treatment. Nano-
particles have been shown to have a potential for early
detection of cancer [42], effective drug delivery that pref-
erentially accumulates the drugs in tumor cells [43] and
potentiate the dose deposit selectively in irradiated tis-
sues [44]. In the current study, we showed that cerium
nanoparticles conjugated with folic acid had a better cel-
lular uptake as folic acid increased the concentration of
NCe in ovarian cancer cells compared to NCe alone,
resulting in better tumor inhibition and further enhance-
ment of the tumoricidal effect of cisplatinum.
Cancer cells are highly dependent on folate for replica-
tion, and they even develop their own receptors that are
not overexpressed on noncancerous cells, which makes
it an excellent avenue for targeted anticancer treatment
[45, 46]. We previously showed that NCe has significant
anticancer effect on ovarian cancer cell lines secondary
to its antioxidant and antiangiogenic properties [6]. We
exploited this differential expression of folic acid recep-
tors on cancer and somatic cells and demonstrated that
conjugation of NCe with folic acid potentiated the NCe's
therapeutic effect on ovarian cancer. One of the mecha-
nisms for the higher efficacy might be higher intracellular
Fig. 6 NCe-FA enhances apoptosis and ROS in combination with cisplatinum. a Representative caspase-3 staining of the tumor tissue, indicating
cells undergoing apoptosis and b 4 hydroxynonenal, indicating presence of oxidative stress, from various treatment groups (200×). Expression
was visualized as a positive brown stain. Each stained picture is representative of at least 5 different fields examined from 3 individual slides
stained per group. Quantification of the stain was performed on a scale of 0–3; 0–1 for no or weak stain; 2 for moderate stain and 3 for strong
stain. Average score is represented as a respective bar graph. *p < 0.001, *p < 0.05
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accumulation of folic acid tagged particles. NCe-FA had
significantly increased uptake by the cells, indicating that
the conjugation with folic acid indeed enabled NCe to
specifically target the cancer cells.
Tumor angiogenesis is essential for delivering oxygen
and other nutrients to the growing tumor and is charac-
terized by either excess production of pro-angiogenic
signals or lack of angiogenesis inhibitors [47–49]. Re-
cently, inhibition of tumor angiogenesis has become a
clinical anticancer strategy and only a few new drugs
have been approved by the U.S. Food and Drug Admin-
istration for ovarian cancer since 2006, including an
anti-angiogenic agent, bevacizumab [50]. In our previous
study, NCe was found to have significant antiangiogenic
properties that is independent of VEGF production in
vitro and in vivo. We speculated that this might be sec-
ondary to inhibition of new vessel formation by targeting
endothelial cells. In the current study, we examined the
microvessel density in each group and found a signifi-
cant reduction in formation of new vessels in NCe-FA
and NCe-FA/cisplatinum treated groups compared to
the untreated group as evident from decreased expres-
sion of CD31, a marker for endothelial cells. However,
the NCe-FA and cisplatinum combination and cisplati-
num alone groups showed similar CD31 density despite
the fact that a lower tumor burden score was achieved
with NCe-FA and cisplatinum treatment. Although the
vessel density was similar, there might be a possibility
that the integrity of the vessels may be more compro-
mised in the combination group, resulting in nonfunc-
tional vasculature, hence more reduced tumor growth.
Additionally, NCe-FA also reduced the expression of the
EMT marker, vimentin [34], indicating its ability to
maybe limit ovarian tumor metastasis. This supports our
observation of reduced tumor nodules on the abdominal
organs in the treated groups.
NCe particles have a dual effect on ROS generation
that is mainly dependent on the pH of the environment
[7]. In the previous study, we showed that NCe (with
higher Ce3+; ~62 %) has significant antioxidant proper-
ties and decreased the ROS generation in A2780 cell
lines in vitro. However, in the current study, a different
formulation of NCe (with lower Ce3+ [~24 %] as com-
pared to the study published earlier) and NCe-FA conju-
gation increased the ROS. This might be secondary to
the pH of the cancer cells. Wason et al. suggested that
NCe acts primarily as a producer of H2O2 in (acidic) a
cancer environment and a scavenger of H2O2 in (neutral)
normal tissues [9]. In particular, NCe converts superoxide
radicals to H2O2; however, in an acidic condition pH
suppress NCe catalase mimetic activity, which causes
accumulation of H2O2 within the cells. In the pres-
ence of Fe ions, H2O2 can go through Fenton medi-
ated reaction and might generate reactive radicals.
Chemotherapy agents, such as anthracyclines and
platinum complexes, also generate ROS and cause
chemotherapy associated oxidative stress [51]. This
eventually decreases cell proliferation [51]. The com-
bination of NCe-FA and cisplatinum showed the
strongest positive expression of 4 hydroxynonenal
(oxidative stress marker) as they both increased the
ROS production and eventually caused oxidative
stress. These data are in accordance to the previous
publication where NCe was shown to induce ROS
generation in squamous carcinoma cells [7] and pan-
creatic cancer cells [9].
Conclusion
In conclusion, conjugation of nanoparticle cerium oxide
with folic acid has significant in vivo and in vitro antitu-
mor activity in ovarian cancer and combination treat-
ment with cisplatinum has enhanced this activity. In the
future, using novel technologies including nanomedicine
particles and modifying them in a more tumor targeted
fashion given with or without conventional chemother-
apy would provide better clinical outcomes with less tox-
icity and offer a superior treatment modality and hope
to our patients with ovarian cancer.
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